ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

MADRID, SPAIN and CAMBRIDGE MA.

• This first approval received from the AEMPS in SPAIN

• The company expects to start enrollment this quarter

• This is the second Phase II study in CNS with the drug

• Approvals from other European agencies expected soon

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that it has received approval of a Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Agency (AEMPS) to conduct a Phase IIa clinical study with ORY-2001 in patients of Alzheimer’s disease (AD). The study will be conducted in different European hospitals in Spain, and also in UK and France once the corresponding approvals from the UK and French regulatory authorities are obtained.

Click here to see the full Press Release